Erkan Kalafat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Erkan Kalafat has a total of 347 co-authors. Here are the top co-authors by number of shared publications:
- Asma Khalil
Fetal Medicine Unit St George's University Hospital London UK
30 shared publications - Acar Koç
ANKARA ÜNİVERSİTESİ, ANKARA TIP FAKÜLTESİ
12 shared publications Basky Thilaganathan
From the Fetal Medicine Unit, St George's Hospital, St George's University of London, United Kingdom (H.P., E.K., B.T., A.K.).
11 shared publications- Tuncay Yüce
Department of Obstetric and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkey
9 shared publications - Baskaran Thilaganathan
Fetal Medicine Unit St George's University Hospitals NHS Foundation Trust London UK
8 shared publications - Julia Binder
Department of Obstetrics and Feto‐maternal Medicine Medical University of Vienna Vienna Austria
8 shared publications
Latest Publications
- 1 June 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (6)
Effects of Antihypertensive Therapy on Pre- and Postnatal Maternal Hemodynamics
BACKGROUND: Hypertensive disorders of pregnancy (HDP) are associated with cardiovascular impairment reflected by abnormal maternal hemodynamics. Current treatment strategies target blood pressure rather than the maternal hemodynamic profile. Therefore, this study evaluated the effects of antihypertensive treatment on cardiovascular parameters in women with HDP, healthy pregnant women, and in a preeclamptic rat model. METHODS: This multicenter, prospective translational case-control study was conducted at the Medical University of Vienna and the Max Delbruck Center for Molecular Medicine, Berlin, between July 2019 and July 2024. Cardiovascular parameters including cardiac output, stroke volume, systemic vascular resistance, and inotropy index were measured pre- and posttreatment with α-methyldopa as well as postnatally using the USCOM 1A Monitor. In the rat model, the effects of α-methyldopa, nifedipine, and labetalol were evaluated. RESULTS: A total of 238 women were included: 132 with HDP (69 gestational hypertension, 63 preeclampsia) and 106 controls. In gestational hypertension, treatment led to increased cardiac output (median, 0.38 L/min [95% CI, 0.06–0.71]; P =0.021) and a decrease in systemic vascular resistance (median, −0.08 log dynes/s per cm −5 [95% CI, −0.14 to −0.03]; P =0.005). In preeclampsia, no significant hemodynamic changes were observed. Systemic vascular resistance remained elevated and stroke volume index reduced in both HDP groups up to 1-year postpartum. Similar patterns were observed in the preeclamptic rat model, with persistently increased vascular resistance and reduced cardiac output and stroke volume. CONCLUSIONS: Antihypertensive therapy does not influence cardiovascular impairment despite lowering blood pressure in preeclampsia. Novel therapeutic approaches are needed to improve maternal cardiovascular health after HDP.
- 1 June 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (6)
Effects of Antihypertensive Therapy on Pre- and Postnatal Maternal Hemodynamics
BACKGROUND: Hypertensive disorders of pregnancy (HDP) are associated with cardiovascular impairment reflected by abnormal maternal hemodynamics. Current treatment strategies target blood pressure rather than the maternal hemodynamic profile. Therefore, this study evaluated the effects of antihypertensive treatment on cardiovascular parameters in women with HDP, healthy pregnant women, and in a preeclamptic rat model. METHODS: This multicenter, prospective translational case-control study was conducted at the Medical University of Vienna and the Max Delbruck Center for Molecular Medicine, Berlin, between July 2019 and July 2024. Cardiovascular parameters including cardiac output, stroke volume, systemic vascular resistance, and inotropy index were measured pre- and posttreatment with α-methyldopa as well as postnatally using the USCOM 1A Monitor. In the rat model, the effects of α-methyldopa, nifedipine, and labetalol were evaluated. RESULTS: A total of 238 women were included: 132 with HDP (69 gestational hypertension, 63 preeclampsia) and 106 controls. In gestational hypertension, treatment led to increased cardiac output (median, 0.38 L/min [95% CI, 0.06–0.71]; P =0.021) and a decrease in systemic vascular resistance (median, −0.08 log dynes/s per cm −5 [95% CI, −0.14 to −0.03]; P =0.005). In preeclampsia, no significant hemodynamic changes were observed. Systemic vascular resistance remained elevated and stroke volume index reduced in both HDP groups up to 1-year postpartum. Similar patterns were observed in the preeclamptic rat model, with persistently increased vascular resistance and reduced cardiac output and stroke volume. CONCLUSIONS: Antihypertensive therapy does not influence cardiovascular impairment despite lowering blood pressure in preeclampsia. Novel therapeutic approaches are needed to improve maternal cardiovascular health after HDP.
- Open Access
- 24 May 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 67 (6) , 824-835
Predicting live birth following single euploid frozen‐embryo transfer via β‐ hCG dynamics: iHOPE prognostic model with external validation
Objectives: To determine the prognostic value of serum β ‐human chorionic gonadotropin ( β ‐hCG) for predicting live birth following single euploid frozen‐embryo transfer (FET), and to develop and validate a prognostic model (iHOPE) for this purpose. Methods: This retrospective cohort study used data from two large fertility practices. The model development cohort included 1581 women with a positive β ‐hCG test after single euploid FET in the United Arab Emirates between March 2017 and June 2023. The external validation cohort comprised 1171 women who underwent FET (with or without preimplantation genetic testing for aneuploidy (PGT‐A)) resulting in a positive β ‐hCG test between January 2020 and December 2023 in the USA. β ‐hCG level was measured on approximately day 10 after FET and was repeated thereafter, allowing estimation of the daily increase in β ‐hCG. The association of clinical and embryological factors with initial β ‐hCG level and subsequent daily β ‐hCG increase was evaluated using multivariable linear regression analysis. The iHOPE prognostic model for live birth was built using repeated measurements of β ‐hCG following single euploid FET, and was validated internally and externally. Model performance was evaluated using the area under the receiver‐operating‐characteristics curve (AUC) and calibration slope. Results: Of 1581 pregnancies in the model development cohort, 1191 (75.3%) resulted in live birth. Of 1171 pregnancies in the external validation cohort, 395 were from an untested embryo, of which 261 (66.1%) resulted in live birth, and 776 were from a PGT‐A‐tested embryo, of which 566 (72.9%) resulted in live birth. In the model development cohort, trophectoderm quality was associated significantly with initial β ‐hCG level Z ‐score among pregnancies resulting in live birth (Grade B vs Grade A: β , −0.19 (95% CI, −0.34 to −0.04), P = 0.011; Grade C vs Grade A: β , −0.59 (95% CI, −0.83 to −0.35), P < 0.001). Women with a higher body mass index (BMI) had a lower initial β ‐hCG level Z ‐score and lower subsequent β ‐hCG increase among pregnancies resulting in live birth ( P < 0.001 for both). Compared with pregnancy resulting in live birth, early clinical pregnancy loss, biochemical pregnancy and pregnancy of unknown location/ectopic pregnancy had significantly lower initial β ‐hCG level Z ‐scores and lower subsequent β ‐hCG increases ( P < 0.001 for all). On internal cross‐validation, the iHOPE prognostic model based on repeated β ‐hCG measurements had a mean ± SD AUC of 0.79 ± 0.04 and good calibration for probabilistic estimation of live birth. In the external validation cohort, trophectoderm quality (Grade B vs Grade A: β , −0.19 (95% CI, −0.34 to −0.05), P = 0.007; Grade C vs Grade A: β , −0.63 (95% CI, −0.90 to −0.37), P < 0.001), time of expanded blastulation ( β , −0.02 (95% CI, −0.02 to −0.01), P < 0.001), patient BMI ( β , −0.04 (95% CI, −0.05 to −0.03), P < 0.001) and PGT‐A testing ( β , −0.16 (95% CI, −0.30 to −0.03), P = 0.017) were associated significantly with initial β ‐hCG level Z ‐score. On external validation, the AUC for the prediction of live birth using the repeated‐measurements model was 0.79 (95% CI, 0.75–0.83) and 0.84 (95% CI, 0.80–0.88) for PGT‐A‐tested and untested embryos, respectively. Calibration in the external validation cohort was better for PGT‐A‐tested embryos compared with untested embryos, as the model slightly overpredicted live‐birth probabilities in the latter group. The iHOPE model is available for use online and as a mobile application. Conclusions: Initial serum β ‐hCG level following FET is affected by PGT‐A. The iHOPE prognostic model, using repeated β ‐hCG measurements, demonstrates robust calibration and acceptable predictive capability for live birth. It may prove to be a useful tool for clinical monitoring and managing patient expectations, and could aid in the early detection of abnormal early pregnancy development. iHOPE is intended for prognostic purposes only and predicted probabilities should not be considered diagnostic. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 24 May 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 67 (6) , 824-835
Open AccessPredicting live birth following single euploid frozen‐embryo transfer via β‐ hCG dynamics: iHOPE prognostic model with external validation
Objectives: To determine the prognostic value of serum β ‐human chorionic gonadotropin ( β ‐hCG) for predicting live birth following single euploid frozen‐embryo transfer (FET), and to develop and validate a prognostic model (iHOPE) for this purpose. Methods: This retrospective cohort study used data from two large fertility practices. The model development cohort included 1581 women with a positive β ‐hCG test after single euploid FET in the United Arab Emirates between March 2017 and June 2023. The external validation cohort comprised 1171 women who underwent FET (with or without preimplantation genetic testing for aneuploidy (PGT‐A)) resulting in a positive β ‐hCG test between January 2020 and December 2023 in the USA. β ‐hCG level was measured on approximately day 10 after FET and was repeated thereafter, allowing estimation of the daily increase in β ‐hCG. The association of clinical and embryological factors with initial β ‐hCG level and subsequent daily β ‐hCG increase was evaluated using multivariable linear regression analysis. The iHOPE prognostic model for live birth was built using repeated measurements of β ‐hCG following single euploid FET, and was validated internally and externally. Model performance was evaluated using the area under the receiver‐operating‐characteristics curve (AUC) and calibration slope. Results: Of 1581 pregnancies in the model development cohort, 1191 (75.3%) resulted in live birth. Of 1171 pregnancies in the external validation cohort, 395 were from an untested embryo, of which 261 (66.1%) resulted in live birth, and 776 were from a PGT‐A‐tested embryo, of which 566 (72.9%) resulted in live birth. In the model development cohort, trophectoderm quality was associated significantly with initial β ‐hCG level Z ‐score among pregnancies resulting in live birth (Grade B vs Grade A: β , −0.19 (95% CI, −0.34 to −0.04), P = 0.011; Grade C vs Grade A: β , −0.59 (95% CI, −0.83 to −0.35), P < 0.001). Women with a higher body mass index (BMI) had a lower initial β ‐hCG level Z ‐score and lower subsequent β ‐hCG increase among pregnancies resulting in live birth ( P < 0.001 for both). Compared with pregnancy resulting in live birth, early clinical pregnancy loss, biochemical pregnancy and pregnancy of unknown location/ectopic pregnancy had significantly lower initial β ‐hCG level Z ‐scores and lower subsequent β ‐hCG increases ( P < 0.001 for all). On internal cross‐validation, the iHOPE prognostic model based on repeated β ‐hCG measurements had a mean ± SD AUC of 0.79 ± 0.04 and good calibration for probabilistic estimation of live birth. In the external validation cohort, trophectoderm quality (Grade B vs Grade A: β , −0.19 (95% CI, −0.34 to −0.05), P = 0.007; Grade C vs Grade A: β , −0.63 (95% CI, −0.90 to −0.37), P < 0.001), time of expanded blastulation ( β , −0.02 (95% CI, −0.02 to −0.01), P < 0.001), patient BMI ( β , −0.04 (95% CI, −0.05 to −0.03), P < 0.001) and PGT‐A testing ( β , −0.16 (95% CI, −0.30 to −0.03), P = 0.017) were associated significantly with initial β ‐hCG level Z ‐score. On external validation, the AUC for the prediction of live birth using the repeated‐measurements model was 0.79 (95% CI, 0.75–0.83) and 0.84 (95% CI, 0.80–0.88) for PGT‐A‐tested and untested embryos, respectively. Calibration in the external validation cohort was better for PGT‐A‐tested embryos compared with untested embryos, as the model slightly overpredicted live‐birth probabilities in the latter group. The iHOPE model is available for use online and as a mobile application. Conclusions: Initial serum β ‐hCG level following FET is affected by PGT‐A. The iHOPE prognostic model, using repeated β ‐hCG measurements, demonstrates robust calibration and acceptable predictive capability for live birth. It may prove to be a useful tool for clinical monitoring and managing patient expectations, and could aid in the early detection of abnormal early pregnancy development. iHOPE is intended for prognostic purposes only and predicted probabilities should not be considered diagnostic. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 18 February 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 93
COVID-19 vaccination status during pregnancy and preeclampsia risk: the pandemic-era cohort of the INTERCOVID consortium
- 18 February 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 93
Open AccessCOVID-19 vaccination status during pregnancy and preeclampsia risk: the pandemic-era cohort of the INTERCOVID consortium
- 26 December 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 67 (3) , 401-402
First‐trimester placental microcalcifications are associated with preterm prelabor rupture of membranes
- 26 December 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 67 (3) , 401-402
First‐trimester placental microcalcifications are associated with preterm prelabor rupture of membranes
- Open Access
- 20 November 2025
- Published by Elsevier in F&S Science
- Vol. 7 (1) , 27-34
Dose-dependent modulation of luteinizing hormone receptor expression in human granulosa cells and progesterone production during ovarian stimulation
- 20 November 2025
- Published by Elsevier in F&S Science
- Vol. 7 (1) , 27-34
Open AccessDose-dependent modulation of luteinizing hormone receptor expression in human granulosa cells and progesterone production during ovarian stimulation
- Open Access
- 8 November 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (6) , 754-761
Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia
Objective: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), a marker of cardiac stress, has been proposed as a potential prognostic biomarker for maternal adverse outcome in pre‐eclampsia (PE). This study aimed to evaluate the predictive value of NT‐proBNP for severe maternal adverse outcome in pregnancies with an established diagnosis of PE. Methods: This was a retrospective cohort study of singleton pregnancies diagnosed with PE ≤ 36 weeks of gestation that were assessed at the Medical University of Vienna between January 2018 and December 2023. Maternal serum levels of NT‐proBNP, soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and placental growth factor (PlGF) were measured at the time of PE diagnosis. The primary outcome was the occurrence of a severe maternal adverse event, including intensive care unit admission, maternal death, pulmonary edema and severe neurological complications. Associations between severe maternal adverse outcome and Z ‐scores for NT‐proBNP and the sFlt‐1/PlGF ratio were analyzed using logistic and Cox regression models adjusted for gestational age at sampling and the Z ‐score of the other biomarker. The area under the receiver‐operating‐characteristics (ROC) curve (AUC) was used to assess the discriminative ability of the biomarkers. Results: Of 130 women included in our cohort, 13 (10%) experienced severe maternal adverse outcome. NT‐proBNP levels were significantly higher in this group (median, 688.0 (interquartile range (IQR), 249.6–1038.0) pg/mL vs 106.1 (IQR, 50.6–280.6) pg/mL; P < 0.001). Higher NT‐proBNP Z ‐score was associated significantly with severe maternal adverse outcome (adjusted odds ratio, 3.24 (95% CI, 1.50–7.84); P = 0.005) and predicted shorter time‐to‐delivery with severe maternal adverse outcome (adjusted hazard ratio, 3.08 (95% CI, 1.47–6.44); P = 0.003) after adjusting for gestational age at sampling and sFlt‐1/PlGF ratio Z ‐score. The sFlt‐1/PlGF ratio was not associated significantly with these outcomes. ROC‐curve analysis showed that NT‐proBNP had superior discriminative performance compared with the sFlt‐1/PlGF ratio (AUC, 0.75 (95% CI, 0.61–0.90) vs 0.67 (95% CI, 0.56–0.79)). The performance of both biomarkers improved when combined with gestational age at sampling (AUC, 0.82 (95% CI, 0.71–0.94) vs 0.76 (95% CI, 0.65–0.88)). Conclusion: NT‐proBNP was a strong predictor of severe maternal adverse outcome and time‐to‐delivery in women diagnosed with PE, especially in early‐onset cases. NT‐proBNP may serve as a clinically accessible biomarker for risk stratification and surveillance in women with established PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 8 November 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (6) , 754-761
Open AccessPrognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia
Objective: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), a marker of cardiac stress, has been proposed as a potential prognostic biomarker for maternal adverse outcome in pre‐eclampsia (PE). This study aimed to evaluate the predictive value of NT‐proBNP for severe maternal adverse outcome in pregnancies with an established diagnosis of PE. Methods: This was a retrospective cohort study of singleton pregnancies diagnosed with PE ≤ 36 weeks of gestation that were assessed at the Medical University of Vienna between January 2018 and December 2023. Maternal serum levels of NT‐proBNP, soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and placental growth factor (PlGF) were measured at the time of PE diagnosis. The primary outcome was the occurrence of a severe maternal adverse event, including intensive care unit admission, maternal death, pulmonary edema and severe neurological complications. Associations between severe maternal adverse outcome and Z ‐scores for NT‐proBNP and the sFlt‐1/PlGF ratio were analyzed using logistic and Cox regression models adjusted for gestational age at sampling and the Z ‐score of the other biomarker. The area under the receiver‐operating‐characteristics (ROC) curve (AUC) was used to assess the discriminative ability of the biomarkers. Results: Of 130 women included in our cohort, 13 (10%) experienced severe maternal adverse outcome. NT‐proBNP levels were significantly higher in this group (median, 688.0 (interquartile range (IQR), 249.6–1038.0) pg/mL vs 106.1 (IQR, 50.6–280.6) pg/mL; P < 0.001). Higher NT‐proBNP Z ‐score was associated significantly with severe maternal adverse outcome (adjusted odds ratio, 3.24 (95% CI, 1.50–7.84); P = 0.005) and predicted shorter time‐to‐delivery with severe maternal adverse outcome (adjusted hazard ratio, 3.08 (95% CI, 1.47–6.44); P = 0.003) after adjusting for gestational age at sampling and sFlt‐1/PlGF ratio Z ‐score. The sFlt‐1/PlGF ratio was not associated significantly with these outcomes. ROC‐curve analysis showed that NT‐proBNP had superior discriminative performance compared with the sFlt‐1/PlGF ratio (AUC, 0.75 (95% CI, 0.61–0.90) vs 0.67 (95% CI, 0.56–0.79)). The performance of both biomarkers improved when combined with gestational age at sampling (AUC, 0.82 (95% CI, 0.71–0.94) vs 0.76 (95% CI, 0.65–0.88)). Conclusion: NT‐proBNP was a strong predictor of severe maternal adverse outcome and time‐to‐delivery in women diagnosed with PE, especially in early‐onset cases. NT‐proBNP may serve as a clinically accessible biomarker for risk stratification and surveillance in women with established PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 26 October 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (6) , 781-785
Longitudinal assessment of fetal myocardial performance index in normal pregnancy using spectral tissue Doppler
Objective: Although spectral tissue Doppler imaging is recognized as the optimal method for assessing the fetal myocardial performance index (MPI), longitudinal reference ranges for fetal MPI measured using spectral tissue Doppler have not been established. Our objective was to use spectral tissue Doppler data to establish gestational‐age‐specific reference ranges from 12–33 weeks for left and right ventricular fetal MPI. Methods: This was a prospective longitudinal study of women aged 18–35 years, with a body mass index below 30 kg/m 2 and a singleton pregnancy conceived spontaneously. Fetal MPI measurements were obtained in the first, second and third trimesters and MPI was determined using spectral tissue Doppler imaging. A generalized additive model for location, scale and shape (GAMLSS) was used to explore the relationship between fetal MPI and gestational age. Model fit was assessed by checking the normality of estimated Z ‐scores across the fitted range and independency from gestational age. Results: Median fetal MPI was determined for the right and left ventricles at 12–13 weeks, 20–21 weeks and 32–33 weeks' gestation in 90 fetuses. Using multilevel regression modeling, weekly reference ranges for each gestational age were created to provide a continuous characterization of normal fetal MPI assessed using spectral tissue Doppler throughout pregnancy. Percentile reference ranges (5 th , 10 th , 25 th , 50 th , 75 th , 90 th and 95 th ) for right and left ventricular fetal MPI were generated from these models, capturing normal variability across gestation. Conclusion: We have established gestational‐age‐specific reference ranges for left and right ventricular fetal MPI using spectral tissue Doppler imaging, thus providing clinicians with an important tool for the early detection of fetal cardiac dysfunction in high‐risk pregnancies. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 26 October 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (6) , 781-785
Open AccessLongitudinal assessment of fetal myocardial performance index in normal pregnancy using spectral tissue Doppler
Objective: Although spectral tissue Doppler imaging is recognized as the optimal method for assessing the fetal myocardial performance index (MPI), longitudinal reference ranges for fetal MPI measured using spectral tissue Doppler have not been established. Our objective was to use spectral tissue Doppler data to establish gestational‐age‐specific reference ranges from 12–33 weeks for left and right ventricular fetal MPI. Methods: This was a prospective longitudinal study of women aged 18–35 years, with a body mass index below 30 kg/m 2 and a singleton pregnancy conceived spontaneously. Fetal MPI measurements were obtained in the first, second and third trimesters and MPI was determined using spectral tissue Doppler imaging. A generalized additive model for location, scale and shape (GAMLSS) was used to explore the relationship between fetal MPI and gestational age. Model fit was assessed by checking the normality of estimated Z ‐scores across the fitted range and independency from gestational age. Results: Median fetal MPI was determined for the right and left ventricles at 12–13 weeks, 20–21 weeks and 32–33 weeks' gestation in 90 fetuses. Using multilevel regression modeling, weekly reference ranges for each gestational age were created to provide a continuous characterization of normal fetal MPI assessed using spectral tissue Doppler throughout pregnancy. Percentile reference ranges (5 th , 10 th , 25 th , 50 th , 75 th , 90 th and 95 th ) for right and left ventricular fetal MPI were generated from these models, capturing normal variability across gestation. Conclusion: We have established gestational‐age‐specific reference ranges for left and right ventricular fetal MPI using spectral tissue Doppler imaging, thus providing clinicians with an important tool for the early detection of fetal cardiac dysfunction in high‐risk pregnancies. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 13 October 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (12) , 4281-4288
Distinct post-insemination dynamics between fresh and frozen-derived gametes using testicular sperm
Purpose To evaluate differences in post-insemination events between fresh and frozen-derived gametes when testicular sperm extraction (TESE) is used. Method A retrospective cohort study including 980 oocytes retrieved across 72 cycles from 30 couples, between January 2017 and September 2023. Gamete sources were fresh (fresh-TESE) or frozen-thawed-TESE (frozen-TESE) from the same patients with non-obstructive azoospermia (NOA), and fresh or vitrified (frozen) oocytes from the same female partner. Following insemination by TESE-sperm, embryos were cultured in a time-lapse (TL) incubator. Resulting blastocysts underwent trophectoderm (TE) biopsy for preimplantation genetic testing for aneuploidy (PGT-A) by next-generation sequencing (NGS). Fertilization, usable blastocysts, and euploidy rates were recorded, and morphokinetic key parameters were annotated. Results Oocyte/sperm dyads using frozen-TESE showed an association with lower fertilization (OR 0.64, 95% CI 0.45–0.89, P = 0.008) and lower blastulation/MII (OR 0.53, 95% CI 0.37–0.77, P = 0.001), but similar blastulation/2PN (OR 0.69, 95% CI 0.45–1.07, P = 0.09). After accounting for female age, euploidy per tested blastocyst was similar whether fresh or frozen-TESE was used, but frozen oocyte use showed no association with these outcomes. The use of frozen dyads was associated with longer duration of 2PN after tPNa to tPNf: in frozen-TESE, 2.10 h longer (95% CI 0.55–3.64, P = 0.008) and in vitrified oocytes, 2.34 h longer (95% CI 0.31–4.36, P = 0.024). Slight morphokinetic differences between fresh and frozen-TESE were observed during subsequent developmental stages. Conclusions Synchronizing fresh-TESE with oocyte retrieval, when possible, appears safer to maximize fertilization rates. Regardless of the gamete type, frozen-sourced sperm or oocyte impact 2PN-lag time, possibly indicating nuclear repair mechanisms post-freezing, requiring further investigation.
- 13 October 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (12) , 4281-4288
Distinct post-insemination dynamics between fresh and frozen-derived gametes using testicular sperm
Purpose To evaluate differences in post-insemination events between fresh and frozen-derived gametes when testicular sperm extraction (TESE) is used. Method A retrospective cohort study including 980 oocytes retrieved across 72 cycles from 30 couples, between January 2017 and September 2023. Gamete sources were fresh (fresh-TESE) or frozen-thawed-TESE (frozen-TESE) from the same patients with non-obstructive azoospermia (NOA), and fresh or vitrified (frozen) oocytes from the same female partner. Following insemination by TESE-sperm, embryos were cultured in a time-lapse (TL) incubator. Resulting blastocysts underwent trophectoderm (TE) biopsy for preimplantation genetic testing for aneuploidy (PGT-A) by next-generation sequencing (NGS). Fertilization, usable blastocysts, and euploidy rates were recorded, and morphokinetic key parameters were annotated. Results Oocyte/sperm dyads using frozen-TESE showed an association with lower fertilization (OR 0.64, 95% CI 0.45–0.89, P = 0.008) and lower blastulation/MII (OR 0.53, 95% CI 0.37–0.77, P = 0.001), but similar blastulation/2PN (OR 0.69, 95% CI 0.45–1.07, P = 0.09). After accounting for female age, euploidy per tested blastocyst was similar whether fresh or frozen-TESE was used, but frozen oocyte use showed no association with these outcomes. The use of frozen dyads was associated with longer duration of 2PN after tPNa to tPNf: in frozen-TESE, 2.10 h longer (95% CI 0.55–3.64, P = 0.008) and in vitrified oocytes, 2.34 h longer (95% CI 0.31–4.36, P = 0.024). Slight morphokinetic differences between fresh and frozen-TESE were observed during subsequent developmental stages. Conclusions Synchronizing fresh-TESE with oocyte retrieval, when possible, appears safer to maximize fertilization rates. Regardless of the gamete type, frozen-sourced sperm or oocyte impact 2PN-lag time, possibly indicating nuclear repair mechanisms post-freezing, requiring further investigation.
- 1 September 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (11) , 2115-2125
Forecasting Outcomes of Assisted Reproductive Treatments Using Artificial Networks (FORTUNE) classification system: a new prognostic model to predict euploid blastocyst yield in patients undergoing IVF
STUDY QUESTION: Can a prediction model classify IVF patients into distinct prognostic groups based on their expected yield of euploid blastocysts? SUMMARY ANSWER: Five distinct prognostic groups were identified, with chance of obtaining at least one euploid blastocyst ranging from <1% to 2% in very poor to ∼95% in very good prognosis groups. WHAT IS KNOWN ALREADY: Euploid blastocyst yield is a critical determinant of IVF success. While female age strongly influences embryo euploidy, other factors like ovarian reserve markers, partner age, and BMI may also contribute. Current approaches rely on basic and somewhat arbitrary classification of ovarian reserve markers and patient age, which are unable to represent the granular multidimensional relationship between them. A systematic approach to classify patients based on their expected euploid yield would enable better treatment planning and patient counseling. STUDY DESIGN, SIZE, DURATION: A retrospective analysis of 10 774 IVF cycles from 8256 couples undergoing pre-implantation genetic testing for aneuploidy (PGT-A) of all available blastocysts from years 2020 to 2023 and a temporal validation cohort of 2089 cycles of 2089 patients from year 2024. The prediction model was developed using generalized additive models for location, scale, and shape using a development cohort from 2020 to 2023, and cross-validated through exhaustive 5-fold cross-validation. Temporal validation was performed using an entirely separate cohort from 2024. Model performance was assessed through calibration plots and discrimination metrics. PARTICIPANTS/MATERIALS, SETTING, METHODS: Couples undergoing IVF with PGT-A of all their available blastocysts were included. Model included female age, partner age, anti-Müllerian hormone (AMH), antral follicle count, and BMI as predictors. Non-linear associations were captured using neural networks and restricted cubic splines. Missing data were handled using multivariate imputation by chained equations. MAIN RESULTS AND THE ROLE OF CHANCE: The median female age was 36.3 years (IQR: 33.3–39.5) and AMH was 2.0 ng/ml (IQR: 1.0–3.8). Models for predicting ≥1, ≥2, and ≥3 euploid blastocysts yield achieved very good discrimination performance in 5-fold cross-validation samples with mean AUCs of 0.834, 0.849, and 0.861, respectively. Models showed negligible shrinkage (<1%) between training and cross-validation sets with near-perfect calibration slopes (mean: 1.00, IQR: 0.99–1.01) and intercepts (mean: 0.015, IQR: 0.00–0.03). Using predicted absolute counts of euploid blastocysts, five distinct prognostic groups were created based on predicted euploid blastocyst yield. Patients in the very poor prognosis group had 98.3% probability of obtaining no euploid blastocysts after stimulation while the probabilities were 80.2%, 47.5%, 15.8%, and 4.7% in poor, borderline, good, and very good prognosis groups. The chances of obtaining ≥3 euploid blastocysts were 79.8%, 43.7%, 8.9%, 0.2%, and 0% in very good, good, borderline, poor, and very poor prognosis groups. In the temporal validation set (n = 2089), which constituted the first cycles of patients that were treated, the rates of no euploid blastocysts obtained at the end of stimulation were 100.0%, 82.6%, 47.4%, 13.1%, and 4.4% in the very poor, poor, borderline, good, and very good prognosis groups. The rates of three or more euploid blastocysts obtained at the end of stimulation in the temporal validation set were 83.5%, 51.0%, 10.7%, 0.6%, and 0.0% for very good, good, borderline, poor, and very poor prognosis groups. The FORTUNE (Forecasting Outcomes of Reproductive Treatments Using artificial Networks) model is available for use and further validation at https://epsilonkappa-analytics.shinyapps.io/FORTUNE and App Store for iOS mobile devices https://apps.apple.com/en/app/fortune-ivf/id6747190429 LIMITATIONS, REASONS FOR CAUTION: Single-center study design may limit generalizability. The model does not account for laboratory-specific factors or stimulation protocols. WIDER IMPLICATIONS OF THE FINDINGS: This novel classification system provides objective, personalized counseling for IVF patients regarding expected euploid yield, enabling better-informed decision-making about treatment options and number of planned stimulation cycles. STUDY FUNDING/COMPETING INTEREST(S): There was no funding needed for this study. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
- 1 September 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (11) , 2115-2125
Forecasting Outcomes of Assisted Reproductive Treatments Using Artificial Networks (FORTUNE) classification system: a new prognostic model to predict euploid blastocyst yield in patients undergoing IVF
STUDY QUESTION: Can a prediction model classify IVF patients into distinct prognostic groups based on their expected yield of euploid blastocysts? SUMMARY ANSWER: Five distinct prognostic groups were identified, with chance of obtaining at least one euploid blastocyst ranging from <1% to 2% in very poor to ∼95% in very good prognosis groups. WHAT IS KNOWN ALREADY: Euploid blastocyst yield is a critical determinant of IVF success. While female age strongly influences embryo euploidy, other factors like ovarian reserve markers, partner age, and BMI may also contribute. Current approaches rely on basic and somewhat arbitrary classification of ovarian reserve markers and patient age, which are unable to represent the granular multidimensional relationship between them. A systematic approach to classify patients based on their expected euploid yield would enable better treatment planning and patient counseling. STUDY DESIGN, SIZE, DURATION: A retrospective analysis of 10 774 IVF cycles from 8256 couples undergoing pre-implantation genetic testing for aneuploidy (PGT-A) of all available blastocysts from years 2020 to 2023 and a temporal validation cohort of 2089 cycles of 2089 patients from year 2024. The prediction model was developed using generalized additive models for location, scale, and shape using a development cohort from 2020 to 2023, and cross-validated through exhaustive 5-fold cross-validation. Temporal validation was performed using an entirely separate cohort from 2024. Model performance was assessed through calibration plots and discrimination metrics. PARTICIPANTS/MATERIALS, SETTING, METHODS: Couples undergoing IVF with PGT-A of all their available blastocysts were included. Model included female age, partner age, anti-Müllerian hormone (AMH), antral follicle count, and BMI as predictors. Non-linear associations were captured using neural networks and restricted cubic splines. Missing data were handled using multivariate imputation by chained equations. MAIN RESULTS AND THE ROLE OF CHANCE: The median female age was 36.3 years (IQR: 33.3–39.5) and AMH was 2.0 ng/ml (IQR: 1.0–3.8). Models for predicting ≥1, ≥2, and ≥3 euploid blastocysts yield achieved very good discrimination performance in 5-fold cross-validation samples with mean AUCs of 0.834, 0.849, and 0.861, respectively. Models showed negligible shrinkage (<1%) between training and cross-validation sets with near-perfect calibration slopes (mean: 1.00, IQR: 0.99–1.01) and intercepts (mean: 0.015, IQR: 0.00–0.03). Using predicted absolute counts of euploid blastocysts, five distinct prognostic groups were created based on predicted euploid blastocyst yield. Patients in the very poor prognosis group had 98.3% probability of obtaining no euploid blastocysts after stimulation while the probabilities were 80.2%, 47.5%, 15.8%, and 4.7% in poor, borderline, good, and very good prognosis groups. The chances of obtaining ≥3 euploid blastocysts were 79.8%, 43.7%, 8.9%, 0.2%, and 0% in very good, good, borderline, poor, and very poor prognosis groups. In the temporal validation set (n = 2089), which constituted the first cycles of patients that were treated, the rates of no euploid blastocysts obtained at the end of stimulation were 100.0%, 82.6%, 47.4%, 13.1%, and 4.4% in the very poor, poor, borderline, good, and very good prognosis groups. The rates of three or more euploid blastocysts obtained at the end of stimulation in the temporal validation set were 83.5%, 51.0%, 10.7%, 0.6%, and 0.0% for very good, good, borderline, poor, and very poor prognosis groups. The FORTUNE (Forecasting Outcomes of Reproductive Treatments Using artificial Networks) model is available for use and further validation at https://epsilonkappa-analytics.shinyapps.io/FORTUNE and App Store for iOS mobile devices https://apps.apple.com/en/app/fortune-ivf/id6747190429 LIMITATIONS, REASONS FOR CAUTION: Single-center study design may limit generalizability. The model does not account for laboratory-specific factors or stimulation protocols. WIDER IMPLICATIONS OF THE FINDINGS: This novel classification system provides objective, personalized counseling for IVF patients regarding expected euploid yield, enabling better-informed decision-making about treatment options and number of planned stimulation cycles. STUDY FUNDING/COMPETING INTEREST(S): There was no funding needed for this study. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. TRIAL REGISTRATION NUMBER: N/A.